CL2019003419A1 - Polipéptidos que antagonizan la señalización wnt en células tumorales. - Google Patents

Polipéptidos que antagonizan la señalización wnt en células tumorales.

Info

Publication number
CL2019003419A1
CL2019003419A1 CL2019003419A CL2019003419A CL2019003419A1 CL 2019003419 A1 CL2019003419 A1 CL 2019003419A1 CL 2019003419 A CL2019003419 A CL 2019003419A CL 2019003419 A CL2019003419 A CL 2019003419A CL 2019003419 A1 CL2019003419 A1 CL 2019003419A1
Authority
CL
Chile
Prior art keywords
polypeptides
tumor cells
wnt signaling
methods
antagonize wnt
Prior art date
Application number
CL2019003419A
Other languages
English (en)
Inventor
Vittoria Zinzalla
Klaus-Peter Kuenkele
Marie-Ange Buyse
Karen Cromie
Stephanie Staelens
Beatrijs Strubbe
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2019003419A1 publication Critical patent/CL2019003419A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA INVENCIÓN PROPORCIONA POLIPÉPTIDOS DE FIJACIÓN A LRP5 NOVEDOSOS Y, MÁS ESPECÍFICAMENTE, CONSTRUCCIONES DE DOMINIO VARIABLE ÚNICO DE INMUNOGLOBULINA DE FIJACIÓN A LRP5 NOVEDOSOS, QUE PUEDEN INHIBIR LAS VÍAS DE SEÑALIZACIÓN WNT. LA INVENCIÓN TAMBIÉN SE REFIERE A SECUENCIAS ESPECÍFICAS DE ESTOS POLIPÉPTIDOS, MÉTODOS PARA SU PRODUCCIÓN Y MÉTODOS PARA USARLOS, QUE INCLUYEN MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES, TALES COMO CÁNCER.
CL2019003419A 2017-05-31 2019-11-25 Polipéptidos que antagonizan la señalización wnt en células tumorales. CL2019003419A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17173782 2017-05-31

Publications (1)

Publication Number Publication Date
CL2019003419A1 true CL2019003419A1 (es) 2020-03-27

Family

ID=59021278

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003419A CL2019003419A1 (es) 2017-05-31 2019-11-25 Polipéptidos que antagonizan la señalización wnt en células tumorales.

Country Status (23)

Country Link
US (2) US11033636B2 (es)
EP (1) EP3630816B1 (es)
JP (1) JP7216024B2 (es)
KR (1) KR102717656B1 (es)
CN (1) CN110637030B (es)
AR (1) AR111840A1 (es)
AU (1) AU2018276409A1 (es)
BR (1) BR112019022729A2 (es)
CA (1) CA3060401A1 (es)
CL (1) CL2019003419A1 (es)
CO (1) CO2019012329A2 (es)
EA (1) EA201992808A1 (es)
ES (1) ES2979194T3 (es)
IL (1) IL270854B2 (es)
MA (1) MA48760A (es)
MX (1) MX2019014331A (es)
MY (1) MY200744A (es)
PE (1) PE20200610A1 (es)
PH (1) PH12019502602A1 (es)
PL (1) PL3630816T3 (es)
TW (1) TW201906858A (es)
UA (1) UA125761C2 (es)
WO (1) WO2018220080A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018276409A1 (en) * 2017-05-31 2019-10-31 Boehringer Ingelheim International Gmbh Polypeptides antagonizing Wnt signaling in tumor cells
GB2597623A (en) 2017-08-07 2022-02-02 Univ California Platform for generating safe cell therapeutics
WO2019126398A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Wnt surrogate molecules and uses thereof
JP7317016B2 (ja) 2017-12-19 2023-07-28 スロゼン オペレーティング， インコーポレイテッド 抗ｌｒｐ５／６抗体及び使用方法
WO2019126399A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Anti-frizzled antibodies and methods of use
WO2020080941A1 (en) * 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
US20220112278A1 (en) * 2019-02-11 2022-04-14 Surrozen, Inc. Modulation of wnt signalling in ocular disorders
EP3946617A1 (en) * 2019-03-29 2022-02-09 Boehringer Ingelheim International GmbH Anticancer combination therapy
KR20220078568A (ko) * 2019-08-14 2022-06-10 모드맵 테라퓨틱스 인코포레이티드 Lrp5 단백질에 결합하는 항체 및 사용 방법
KR20230011226A (ko) * 2021-07-13 2023-01-20 인제대학교 산학협력단 NEURL 유전자, 이를 포함하는 발현벡터 또는 NEURL 단백질을 유효성분으로 포함하는 β-카테닌 과발현으로 인한 암질환 예방 또는 치료용 약학조성물
JP2024530656A (ja) * 2021-08-10 2024-08-23 ヒート バイオロジクス，インコーポレイテッド． 新規Ｔｉｍ－４結合剤の作製及び特性決定
CN114702588B (zh) * 2022-04-27 2022-11-22 博际生物医药科技(杭州)有限公司 抗Nectin-4抗体和双特异性抗体
WO2023250402A2 (en) * 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2192131A1 (en) 1992-08-21 2010-06-02 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6545137B1 (en) 1997-04-15 2003-04-08 John A. Todd Receptor
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
CA2405557C (en) 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP1395285A4 (en) 2001-05-17 2005-06-01 Genome Therapeutics Corp REAGENTS AND METHODS FOR MODULATING INDUCED DKK INTERACTIONS
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP2135879A3 (en) * 2002-06-28 2010-06-23 Domantis Limited Ligand
AU2003286004A1 (en) 2002-11-08 2004-06-07 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
CA2583017A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
EP2172484A3 (en) 2005-05-18 2010-05-19 Ablynx N.V. Serum albumin binding proteins
US20090220488A1 (en) * 2005-08-31 2009-09-03 Humphrey Gardner Evaluating and treating scleroderma
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
WO2008028977A2 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
EP2097449A1 (en) 2006-12-05 2009-09-09 Ablynx N.V. Peptides capable of binding to serum proteins
GB2470328A (en) 2008-03-05 2010-11-17 Ablynx Nv Novel antigen binding dimer complexes, methods of making and uses thereof
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
US8716243B2 (en) 2008-05-28 2014-05-06 St. Jude Childen's Research Hospital Methods of effecting Wnt signaling through Dkk structural analysis
EP3498731A1 (en) 2009-12-23 2019-06-19 ESBATech, an Alcon Biomedical Research Unit LLC Method for decreasing immunogenicity
EP2531523A1 (en) 2010-02-05 2012-12-12 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
PE20130527A1 (es) 2010-03-03 2013-05-09 Boehringer Ingelheim Int Polipeptidos de union a a-beta biparatopicos
AU2011232514A1 (en) * 2010-03-24 2012-08-30 Genentech, Inc. Anti-LRP6 antibodies
JP2013527762A (ja) * 2010-05-06 2013-07-04 ノバルティス アーゲー 治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）抗体の組成物および使用方法
US9290573B2 (en) 2010-05-06 2016-03-22 Novartis Ag Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
CN103501799A (zh) * 2011-01-28 2014-01-08 莱兰斯坦福初级大学评议会 Wnt组合物及其使用方法
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US8790650B2 (en) 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
EP2723769B2 (en) 2011-06-23 2022-06-15 Ablynx NV Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
UA118833C2 (uk) 2011-08-17 2019-03-25 Ґлаксо Ґруп Лімітед Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1
AU2012332263A1 (en) 2011-11-04 2014-05-22 Novartis Ag Low density lipoprotein-related protein 6 (LRP6) - half life extender constructs
TW201335187A (zh) 2012-01-18 2013-09-01 Genentech Inc 抗ｌｒｐ５抗體及使用方法
US11332519B2 (en) * 2015-11-18 2022-05-17 Ablynx N.V. Serum albumin binders
MA43368B1 (fr) * 2015-12-04 2020-09-30 Boehringer Ingelheim Int Polypeptides biparatopiques antagonistes de la signalisation wnt dans des cellules tumorales
AU2018276409A1 (en) * 2017-05-31 2019-10-31 Boehringer Ingelheim International Gmbh Polypeptides antagonizing Wnt signaling in tumor cells
EP3946617A1 (en) * 2019-03-29 2022-02-09 Boehringer Ingelheim International GmbH Anticancer combination therapy

Also Published As

Publication number Publication date
MX2019014331A (es) 2020-01-27
CA3060401A1 (en) 2018-12-06
AR111840A1 (es) 2019-08-21
CN110637030A (zh) 2019-12-31
EP3630816C0 (en) 2024-03-20
ES2979194T3 (es) 2024-09-24
KR20200011933A (ko) 2020-02-04
EP3630816A1 (en) 2020-04-08
IL270854B (en) 2022-10-01
IL270854A (en) 2020-01-30
PE20200610A1 (es) 2020-03-10
MY200744A (en) 2024-01-13
KR102717656B1 (ko) 2024-10-14
US11033636B2 (en) 2021-06-15
BR112019022729A2 (pt) 2020-05-19
US20180344868A1 (en) 2018-12-06
TW201906858A (zh) 2019-02-16
EA201992808A1 (ru) 2020-05-14
US20220362393A1 (en) 2022-11-17
EP3630816B1 (en) 2024-03-20
AU2018276409A1 (en) 2019-10-31
JP2020521478A (ja) 2020-07-27
CO2019012329A2 (es) 2020-01-17
MA48760A (fr) 2020-04-08
PH12019502602A1 (en) 2020-06-08
CN110637030B (zh) 2024-06-11
IL270854B2 (en) 2023-02-01
JP7216024B2 (ja) 2023-01-31
WO2018220080A1 (en) 2018-12-06
PL3630816T3 (pl) 2024-08-05
UA125761C2 (uk) 2022-06-01

Similar Documents

Publication Publication Date Title
CL2019003419A1 (es) Polipéptidos que antagonizan la señalización wnt en células tumorales.
CO2018005680A2 (es) Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales
ECSP17062716A (es) Heterociclos bicíclicos como inhibidores de fgfr4
CY1122415T1 (el) Κυκλοπροπυλαμινες ως lsd1 αναστολεις
CY1122314T1 (el) Κυκλοπροπυλαμινες ως αναστολεις lsd1
CL2019002461A1 (es) Arn terapéutico.
CY1122227T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
MD3582853T2 (ro) Compuși di-nucleotidici ciclici pentru tratamentul cancerului
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
CO2017011484A2 (es) Inhibidores de bromodominio
UY37018A (es) Inhibidores bicíclicos de pad4
EA201592005A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
EA201691725A1 (ru) Соединения для лечения опосредованных комплементом нарушений
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
CY1123031T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
UY37017A (es) Inhibidores aza-bencimidazol de pad4
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
UY37980A (es) Compuestos novedosos para tratar enfermedades parasitarias
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
BR112018068798A2 (pt) composições e métodos para tratamento de doenças parasíticas